Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial

Clinical Therapeutics
Simon HellerBruce Bode

Abstract

The primary study objective was to determine whether insulin detemir (detemir) was noninferior to insulin glargine (glargine) as the basal insulin in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in terms of glycemic control at the end of 52 weeks in patients with type 1 diabetes mellitus (T1DM). This multinational, open-label, parallel-group, treat-to-target, noninferiority trial enrolled patients aged > or = 18 years who had had T1DM for at least 12 months, had been taking a basal-bolus insulin regimen for at least 3 months, and had a glycosylated hemoglobin (HbA1c) value < or = 11.0% at screening. Patients were randomized in a 2:1 ratio to receive either detemir or glargine for 52 weeks. The basal insulin was initially administered once daily (in the evening) in both groups; if patients in the detemir group were achieving the plasma glucose (PG) target before breakfast but not before dinner, they were switched to twice-daily administration. Glargine was administered once daily throughout the trial, according to its approved labeling. Each patient attended 13 study visits and received 16 scheduled telephone calls from the trial site. The primary efficacy end point was glycemic control (HbA1c) after 52 we...Continue Reading

References

May 5, 1999·Diabetic Medicine : a Journal of the British Diabetic Association
Nov 27, 2002·Diabetes Technology & Therapeutics·Lutz Heinemann
Sep 14, 2004·Pharmaceutical Research·Svend HavelundPeter Kurtzhals
Mar 27, 2007·Diabetic Medicine : a Journal of the British Diabetic Association·T R PieberL I Robertson
Aug 2, 2007·Diabetes/metabolism Research and Reviews·J H DevriesT R Pieber

❮ Previous
Next ❯

Citations

Nov 28, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Yoshiki KusunokiMitsuyoshi Namba
Jun 28, 2011·Diabetes Technology & Therapeutics·Stuart LittlePhilip Home
Aug 26, 2011·Diabetes Technology & Therapeutics·Geremia B BolliEllie S Strock
Jul 28, 2011·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Shinya AbeToshikazu Yamanouchi
Jan 1, 2010·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Jean-Pierre Le Floch
Jan 1, 2010·Sensors·Isabel TorresManuel Aguilar-Diosdado
Jan 1, 2010·Clinical Medicine Insights. Endocrinology and Diabetes·Jason R Young, Carrie McAdam-Marx
Oct 15, 2014·Expert Opinion on Biological Therapy·Gemma SuttonPeter Bramlage
Sep 13, 2013·Diabetes/metabolism Research and Reviews·David R OwensLouis Monnier
Apr 1, 2015·Diabetes Technology & Therapeutics·Edward J BastyrAnnette M Chang
Aug 21, 2012·Journal of Controlled Release : Official Journal of the Controlled Release Society·Mayura Oak, Jagdish Singh
Oct 29, 2015·Diabetes/metabolism Research and Reviews·Jeremy PettusSteven Edelman
Jan 8, 2014·The Annals of Pharmacotherapy·Juliet P WallaceM Shawn McFarland
Jun 2, 2015·Contemporary Clinical Trials·Emily PeckhamDavid J Torgerson
Apr 22, 2017·Nature Reviews. Endocrinology·Chantal MathieuKatrien Benhalima
May 31, 2014·Journal of Diabetes Science and Technology·Mukul Minocha, Jogarao Gobburu
Oct 31, 2017·Current Diabetes Reports·Ulrik Pedersen-Bjergaard, Birger Thorsteinsson
Jan 28, 2009·Diabetes/metabolism Research and Reviews·Daniela BruttomessoAldo Baritussio
May 10, 2011·Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·Eda CengizWilliam V Tamborlane
Jul 8, 2011·The Cochrane Database of Systematic Reviews·Sanne G SwinnenJ Hans Devries
Sep 6, 2018·Therapeutic Advances in Endocrinology and Metabolism·Thales B C SilvaJuliana Alvares

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.